Nisoldipine labels and packages: Difference between revisions

Revision as of 05:50, 20 February 2014

Nisoldipine
SULAR^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Nisoldipine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Abdurahman Khalil, M.D. [2]

For patient information about Nisoldipine, click here.

Manufactured for: Shionogi Inc. Florham Park, NJ 07932

By:

SkyePharma Production SAS 38291 Saint Quentin-Fallavier, France Made in France

SLG-PI-07 Rev 02/12

PRINCIPAL DISPLAY PANEL

NDC: 59630-500-10 8.5 mg Extended Release tablets Sular® (nisoldipine) 100 Tablets Rx Only

PRINCIPAL DISPLAY PANEL

NDC: 59630-501-10 17 mg Extended Release tablets Sular® (nisoldipine) 100 Tablets Rx Only

PRINCIPAL DISPLAY PANEL

NDC: 59630-502-10 25.5 mg Extended Release tablets Sular® (nisoldipine) 100 Tablets Rx Only

PRINCIPAL DISPLAY PANEL

NDC: 59630-503-10 34 mg Extended Release tablets Sular® (nisoldipine) 100 Tablets Rx Only

@@ Line 71: / Line 71: @@
 {|
-| [[image:Sular3.jpg]]
+| [[image:Sular3.jpg|400px|thumb]]
 |}